The Plasticity of CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup>CD127<sup>low</sup> T Cells in Patients with Metastatic Renal Cell Carcinoma in the Course of Interferon-Alpha Immunotherapy

<div>The absolute number of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>CD12<svg height="12.3641pt" id="M15" style="vertical-align:-0.2064009pt" version="1.1" viewbox="-0.0498162 -12.1577 20.2791 12.3641" width="20.2791pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M447 623H65C61 580 56 530 47 475H76C100 541 106 550 172 550H388C308 376 196 170 91 -1L98 -12L172 -2C268 204 360 408 455 611L447 623Z" id="g113-56"></path></g><g transform="matrix(.0091,0,0,-0.0091,6.242,-5.741)"><path d="M244 0V30C178 35 170 41 170 107V710C136 697 72 680 18 675V647C83 642 89 639 89 572V107C89 43 80 35 16 30V0H244Z" id="g58-106"></path></g><g transform="matrix(.0091,0,0,-0.0091,8.608,-5.741)"><path d="M262 451C169 451 38 375 38 210C38 98 121 -12 261 -12C360 -12 481 64 481 227C481 351 386 451 262 451ZM249 414C337 414 385 320 385 204C385 70 333 25 272 25C189 25 134 117 134 241C134 355 189 414 249 414Z" id="g58-109"></path></g><g transform="matrix(.0091,0,0,-0.0091,13.167,-5.741)"><path d="M708 439H523V409C587 401 594 395 581 344C562 272 534 184 513 118H511C468 225 428 330 391 434H361C318 317 283 217 244 121H242C218 196 193 273 170 349C157 394 160 401 220 409V439H10V409C60 403 67 394 86 343C127 224 165 109 201 -10H233C273 101 314 199 353 299C393 195 432 99 475 -10H507C554 126 596 251 627 334C648 390 657 401 708 409V439Z" id="g58-117"></path></g></svg> T cells in 1 mcl of peripheral blood in patients with mRCC before and 2 months after immunotherapy.</div>

Journal of Oncology

fig2

Figure 2

Figure 2: The Plasticity of CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup>CD127<sup>low</sup> T Cells in Patients with Metastatic Renal Cell Carcinoma in the Course of Interferon-Alpha Immunotherapy 

Figure 2 | The Plasticity of CD4+CD25+FOXP3+CD127low T Cells in Patients with Metastatic Renal Cell Carcinoma in the Course of Interferon-Alpha Immunotherapy 